Phenotypic Characteristics and Melanoma Thickness in Women
DOI:
https://doi.org/10.2340/00015555-3806Keywords:
cohort study, pigmentary characteristics, melanoma, prognosis, tumour thickness, naeviAbstract
Patients’ phenotypic characteristics might be associated with melanoma aggressiveness, but the evidence is scarce. This study examined the associations between pigmentary characteristics, naevi and melanoma thickness. Data from the Norwegian Women and Cancer (NOWAC) study were analysed. By 2014, 1,243 women were diagnosed with a primary melanoma, and 1,140 had information on thickness. Using ordinal logistic regression models, the probability of being diagnosed with a specific thickness category was calculated by pigmentary score and naevi. Fair pigmentary score was associated with thinner trunk melanomas (probabilities of being diagnosed with a tumour ≤1.0 mm thickness were 74%, 66%, and 51% for fair, medium and dark pigmentary scores, respectively), but not the other sites. High number of naevi was associated with thicker nodular melanoma (NM) but not with superficial spreading melanoma. These findings suggest the need for greater overall vigilance and skin checks among women with fair pigmentary score. The association between naevi and NM suggest possible biological mechanisms.
Downloads
References
Berwick M, Buller DB, Cust A, Gallagher R, Lee TK, Meyskens F, et al. Melanoma epidemiology and prevention. Cancer Treat Res 2016; 167: 17-49.
DOI: https://doi.org/10.1007/978-3-319-22539-5_2
Veierod MB, Adami HO, Lund E, Armstrong BK, Weiderpass E. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev 2010; 19: 111-120.
DOI: https://doi.org/10.1158/1055-9965.EPI-09-0567
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472-492.
DOI: https://doi.org/10.3322/caac.21409
Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979; 86: 343-351.
Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011; 29: 2199-2205.
DOI: https://doi.org/10.1200/JCO.2010.31.5812
Scolyer RA, Shaw HM, Thompson JF, Li LX, Colman MH, Lo SK, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 2003; 27: 1571-1576.
DOI: https://doi.org/10.1097/00000478-200312000-00011
Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002; 95: 1562-1568.
DOI: https://doi.org/10.1002/cncr.10880
Swetter SM, Pollitt RA, Johnson TM, Brooks DR, Geller AC. Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. Cancer 2012; 118: 3725-3734.
DOI: https://doi.org/10.1002/cncr.26707
Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006; 142: 1551-1558.
DOI: https://doi.org/10.1001/archderm.142.12.1551
Cadby G, Ward SV, Cole JM, Moses EK, Millward M, Palmer LJ. The association of host and genetic melanoma risk factors with Breslow thickness in the Western Australian Melanoma Health Study. Br J Dermatol 2014; 170: 851-857.
DOI: https://doi.org/10.1111/bjd.12829
Li WQ, Cho E, Wu S, Li S, Matthews NH, Qureshi AA. Host characteristics and risk of incident melanoma by Breslow thickness. Cancer Epidemiol Biomarkers Prev 2019; 28: 217-224.
DOI: https://doi.org/10.1158/1055-9965.EPI-18-0607
Lund E, Dumeaux V, Braaten T, Hjartåker A, Engeset D, Skeie G, et al. Cohort profile: the Norwegian Women and Cancer Study-NOWAC-Kvinner og kreft. Int J Epidemiol 2008; 37: 36-41.
DOI: https://doi.org/10.1093/ije/dym137
Veierod MB, Parr CL, Lund E, Hjartaker A. Reproducibility of self-reported melanoma risk factors in a large cohort study of Norwegian women. Melanoma Res 2008; 18: 1-9.
DOI: https://doi.org/10.1097/CMR.0b013e3282f120d2
Hosmer Jr DW, Lemeshow S, Sturdivant RX. Applied logistic regression. Hoboken, New Jersey. John Wiley & Sons; 2013.
DOI: https://doi.org/10.1002/9781118548387
Green AC, Viros A, Hughes MCB, Gaudy-Marqueste C, Akhras V, Cook MG, et al. Nodular melanoma: a histopathologic entity? Acta Derm Venereol 2018; 98: 460-462.
DOI: https://doi.org/10.2340/00015555-2855
Mar V, Roberts H, Wolfe R, English DR, Kelly JW. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Austral J Am Acad Dermatol 2013; 68: 568-575.
DOI: https://doi.org/10.1016/j.jaad.2012.09.047
Baumert J, Plewig G, Volkenandt M, Schmid-Wendtner MH. Factors associated with a high tumour thickness in patients with melanoma. Br J Dermatol 2007; 156: 938-944.
DOI: https://doi.org/10.1111/j.1365-2133.2007.07805.x
Duffy DL, Box NF, Chen W, Palmer JS, Montgomery GW, James MR, et al. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet 2004; 13: 447-461.
DOI: https://doi.org/10.1093/hmg/ddh043
Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, et al. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer 2010; 116: 2416-2428.
DOI: https://doi.org/10.1002/cncr.24994
Pena-Vilabelda M, Garcia-Casado Z, Requena C, Traves V, Lopez-Guerrero J, Guillen C, et al. Clinical characteristics of patients with cutaneous melanoma according to variants in the melanocortin 1 receptor gene. Actas Dermosifiliogr 2014; 105: 159-171.
DOI: https://doi.org/10.1016/j.adengl.2013.10.004
Caini S, Gandini S, Botta F, Tagliabue E, Raimondi S, Nagore E, et al. MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. Melanoma Res 2020; 30: 500-510.
DOI: https://doi.org/10.1097/CMR.0000000000000668
Taylor NJ, Busam KJ, From L, Groben PA, Anton-Culver H, Cust AE, et al. Inherited variation at MC1R and histological characteristics of primary melanoma. PloS One 2015; 10: e0119920.
DOI: https://doi.org/10.1371/journal.pone.0119920
Davies JR, Randerson-Moor J, Kukalizch K, Harland M, Kumar R, Madhusudan S, et al. Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res 2012; 25: 384-394.
DOI: https://doi.org/10.1111/j.1755-148X.2012.00982.x
Dessinioti C, Geller AC, Stergiopoulou A, Swetter SM, Baltas E, Mayer JE, et al. Nevus count associations with thinner nodular or superficial spreading melanoma. Acta Derm Venereol 2019; 99: 614-615.
DOI: https://doi.org/10.2340/00015555-3142
Ribero S, Davies JR, Requena C, Carrera C, Glass D, Rull R, et al. High nevus counts confer a favorable prognosis in melanoma patients. Int J Cancer 2015; 137: 1691-1698.
DOI: https://doi.org/10.1002/ijc.29525
Geller AC, Mayer JE, Sober AJ, Miller DR, Argenziano G, Johnson TM, et al. Total nevi, atypical nevi, and melanoma thickness: an analysis of 566 patients at 2 US centers. JAMA Dermatol 2016; 152: 413-418.
DOI: https://doi.org/10.1001/jamadermatol.2016.0027
Autier P, Funck-Brentano E, Aegerter P, Boniol M, Saiag P. Re: High nevus counts confer a favorable prognosis in melanoma patients by S ribero and co-workers, published in the International Journal of Cancer, 2015 (online 21 march 2015). Int J Cancer 2015; 137: 3006-3007.
DOI: https://doi.org/10.1002/ijc.29648
Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010; 60: 301-316.
DOI: https://doi.org/10.3322/caac.20074
Bordoni A, Leoni-Parvex S, Peverelli S, Mazzola P, Mazzucchelli L, Spitale A. Opportunistic screening strategy for cutaneous melanoma does not change the incidence of nodular and thick lesions nor reduce mortality: a population-based descriptive study in the European region with the highest incidence. Melanoma Res 2013; 23: 402-407.
DOI: https://doi.org/10.1097/CMR.0b013e328363b015
Crocetti E, Caldarella A, Chiarugi A, Nardini P, Zappa M. The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. Melanoma Res 2010; 20: 422-426.
DOI: https://doi.org/10.1097/CMR.0b013e32833d9d36
Richardson A, Fletcher L, Sneyd M, Cox B, Reeder AI. The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994-2004. N Z Med J 2008; 121: 18-26.
Murray CS, Stockton DL, Doherty VR. Thick melanoma: the challenge persists. Br J Dermatol 2005; 152: 104-109.
DOI: https://doi.org/10.1111/j.1365-2133.2005.06409.x
Bergenmar M, Ringborg U, Månsson EB, Brandberg YJ. Nodular histogenetic type-the most significant factor for thick melanoma: implications for prevention. Melanoma Res 1998; 8: 403-411.
DOI: https://doi.org/10.1097/00008390-199810000-00004
Robsahm TE, Helsing P, Nilssen Y, Vos L, Rizvi SMH, Akslen LA, et al. High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry. Clin Epidemiol 2018; 10: 537-548.
DOI: https://doi.org/10.2147/CLEP.S151246
Reyes-Marcelino G, Tabbakh T, Espinoza D, Sinclair C, Kang YJ, McLoughlin K, et al. Prevalence of skin examination behaviours among Australians over time. Cancer Epidemiol 2021; 70: 101874.
DOI: https://doi.org/10.1016/j.canep.2020.101874
Tsao H, Olazagasti JM, Cordoro KM, Brewer JD, Taylor SC, Bordeaux JS, et al. Early detection of melanoma: reviewing the ABCDEs. J Am Acad Dermatol 2015; 72: 717-723.
DOI: https://doi.org/10.1016/j.jaad.2015.01.025
Corneli P, Zalaudek I, Rizzi GM, di Meo N. Improving the early diagnosis of early nodular melanoma: can we do better? Expert Rev Anticanc 2018; 18: 1007-1012.
DOI: https://doi.org/10.1080/14737140.2018.1507822
Cancer Registry of Norway. Cancer in Norway 2014 - cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway, 2015. (Access date: November 9, 2020) Available at: http://www.kreftregisteret.no/Global/Cancer%20in%20Norway/2014/cin2014-Special_issue.pdf.
Additional Files
Published
How to Cite
License
Copyright (c) 2021 Reza Ghiasvand, Adèle C. Green, Torkjel M. Sandanger, Elisabete Weiderpass, Trude E. Robsahm, Marit B. Veierød
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
